Another study demonstrated the involvement of the Toll-like receptor 4 pathway and the beneficial use of the TNF-α antagonist infliximab for the treatment of joint inflammation in MPS VI (Simonaro et al., 2010) [40]. This evidence concerns the gene TNF and mucopolysaccharidosis type 6.